![John Zhang](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
John Zhang
Direttore Tecnico/Scientifico/R&S presso IMMUNE PHARMACEUTICALS, INC.
Profilo
John Zhang is currently the Vice President of Research & Development at Immune Pharmaceuticals, Inc. He previously worked as the Director of Preclinical Pharmacology & Toxicology at Pharmacopeia LLC, Head of Toxicology at Enzon Pharmaceuticals, Inc., and Vice President of Preclinical Research & Development at EnzymeRx LLC.
He holds a graduate degree from the University of California, Los Angeles and a doctorate degree from Guangzhou University.
Posizioni attive di John Zhang
Società | Posizione | Inizio |
---|---|---|
IMMUNE PHARMACEUTICALS, INC. | Direttore Tecnico/Scientifico/R&S | 11/12/2017 |
Precedenti posizioni note di John Zhang
Società | Posizione | Fine |
---|---|---|
Pharmacopeia LLC
![]() Pharmacopeia LLC Pharmaceuticals: MajorHealth Technology Pharmacopeia LLC develops small molecule therapeutics to address significant medical needs. The firm operates as clinical development stage Biopharmaceutical Company which focuses on discovering and developing novel small molecule therapeutics to address medical needs. The company was founded by John J. Baldwin in February 2002 and is headquartered in Cranbury, NJ. | Corporate Officer/Principal | - |
ENZON PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
EnzymeRx LLC
![]() EnzymeRx LLC BiotechnologyHealth Technology EnzymeRx LLC develops pegylated uricase for the treatment of resistant and refractory related indications. The company was founded by Anthony S Fiorino in 2008 and is headquartered in Paramus, NJ. | Direttore Tecnico/Scientifico/R&S | - |
Formazione di John Zhang
Guangzhou University | Doctorate Degree |
University of California, Los Angeles | Graduate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
ENZON PHARMACEUTICALS, INC. | Health Technology |
Aziende private | 3 |
---|---|
EnzymeRx LLC
![]() EnzymeRx LLC BiotechnologyHealth Technology EnzymeRx LLC develops pegylated uricase for the treatment of resistant and refractory related indications. The company was founded by Anthony S Fiorino in 2008 and is headquartered in Paramus, NJ. | Health Technology |
Pharmacopeia LLC
![]() Pharmacopeia LLC Pharmaceuticals: MajorHealth Technology Pharmacopeia LLC develops small molecule therapeutics to address significant medical needs. The firm operates as clinical development stage Biopharmaceutical Company which focuses on discovering and developing novel small molecule therapeutics to address medical needs. The company was founded by John J. Baldwin in February 2002 and is headquartered in Cranbury, NJ. | Health Technology |
Immune Pharmaceuticals, Inc.
![]() Immune Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Immune Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Its lead product, Bertilimumab, is a human monoclonal antibody that binds eotaxin-1, a chemokine that attracts eosinophils to the site of inflammation. Bertilimumab has shown promising clinical activity in bullous pemphigoid and has been studied in other conditions including allergic rhinitis and ulcerative colitis, and may have application in other diseases, including atopic dermatitis, asthma, and other diseases. It is also developing NanoCyclo, a topical nano-encapsulated formulation of cyclosporine, for the treatment of atopic dermatitis (AD) and psoriasis. The company was founded by Daniel Gedeon Teper on March 9, 1993 and is headquartered in Englewood Cliffs, NJ. | Health Technology |
- Borsa valori
- Insiders
- John Zhang